Related Experiment Videos
Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Multicentre
Insights
Long-term practolol treatment significantly reduced mortality by 38% in patients after myocardial infarction. This beta-adrenoceptor blockade was particularly beneficial for those with anterior infarction.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Myocardial infarction (MI) poses a significant mortality risk.
- Long-term treatment strategies are crucial for post-MI patient outcomes.
- Beta-adrenoceptor blockade is a key therapeutic class in cardiovascular medicine.
Purpose of the Study:
- To evaluate the efficacy of long-term practolol treatment following myocardial infarction.
- To assess the impact of practolol on mortality and reinfarction rates.
- To identify patient subgroups that benefit most from beta-adrenoceptor blockade.
Main Methods:
- A controlled multicentre trial comparing practolol to placebo.
- Inclusion of updated data for final mortality and reinfarction figures.
- Analysis of outcomes based on infarction location (anterior vs. inferior) and baseline blood pressure.
Main Results:
- A significant 38% reduction in all-cause mortality in the practolol group (p < 0.01).
- No significant difference in non-fatal reinfarction rates between groups.
- Patients with anterior MI, especially those with lower diastolic blood pressure, showed marked benefit.
- Mixed results for inferior MI, with lower early mortality but higher late mortality in the practolol group.
Conclusions:
- Long-term practolol treatment offers significant mortality benefits post-myocardial infarction.
- The benefits are most pronounced in patients with anterior MI.
- Further trials are needed, but up to two years of beta-adrenoceptor blockade is recommended after uncomplicated anterior MI.
Abstract:
In a controlled multicentre trial carried out to assess the value of long-term practolol treatment after myocardial infarction the provisional results showed a significant reduction in mortality, though some of the data were lacking. These have now been included and the results updated. The final figures for all deaths were 78 in the placebo group of 1533 patients and 48 in the practolol group of 1520 patients. The reduction in mortality (38%) was significant at the 1% level. The figures for non-fatal reinfarction (97 in the placebo group, and 75 in the practolol group) were not significantly different. Patients with pre-entry anterior infarction, and especially those with a diastolic blood pressure equal to or below the mean (78 mm Hg) at entry to the trial, were at high risk but benefited particularly well from beta-adrenoceptor blockade. After pre-entry inferior infarction the percentage reduction in deaths occurring within two hours after symptoms of a new event was similar to that after anterior infarction, but the incidence of death more than two hours after the event was greater in the practolol-treated group. Thus the difference between groups in total deaths after pretrial inferior infarction was marginal. Until the results of further trials are reported long-term beta-adrenoceptor blockade (possibly up to two years) is recommended after uncomplicated anterior myocardial infarction.